# Collegium Pharmaceutical, Inc: Form 10-Q for the period ended Sep 30, 2016

- Company: [Collegium Pharmaceutical, Inc](/companies/coll.md) (CIK 1267565)
- Form: 10-Q
- Filed: 2016-11-10
- Accepted by EDGAR: Nov 10, 2016, 16:02 ET
- Period: 2016-09-30
- Accession: 0001558370-16-009927
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1267565/000155837016009927/coll-20160930x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1267565/000155837016009927/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-07-01 to 2016-09-30 | $408.0k | us-gaap:SalesRevenueGoodsNet |
| Revenue | 9 months, 2016-01-01 to 2016-09-30 | $408.0k | us-gaap:SalesRevenueGoodsNet |
| Cost of revenue | 3 months, 2016-07-01 to 2016-09-30 | $29.0k | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2016-01-01 to 2016-09-30 | $29.0k | us-gaap:CostOfGoodsSold |
| Research and development | 3 months, 2016-07-01 to 2016-09-30 | $3.3m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2016-01-01 to 2016-09-30 | $11.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2016-07-01 to 2016-09-30 | $23.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2016-01-01 to 2016-09-30 | $55.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-07-01 to 2016-09-30 | −$26.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2016-01-01 to 2016-09-30 | −$66.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2016-07-01 to 2016-09-30 | $2.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2016-01-01 to 2016-09-30 | $113.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2016-07-01 to 2016-09-30 | −$26.4m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2016-01-01 to 2016-09-30 | −$66.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-07-01 to 2016-09-30 | −$1.13 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 9 months, 2016-01-01 to 2016-09-30 | −$2.85 | us-gaap:EarningsPerShareBasicAndDiluted |
| Basic EPS | 3 months, 2016-07-01 to 2016-09-30 | −$1.13 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2016-01-01 to 2016-09-30 | −$2.85 | us-gaap:EarningsPerShareBasic |
| Capital expenditure | 9 months, 2016-01-01 to 2016-09-30 | $136.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2016-09-30 | $91.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-09-30 | $95.4m | us-gaap:AssetsCurrent |
| Total assets | at 2016-09-30 | $98.7m | us-gaap:Assets |
| Current liabilities | at 2016-09-30 | $22.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2016-09-30 | $24.4m | us-gaap:Liabilities |
| Shareholders' equity | at 2016-09-30 | $74.3m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 25,547 characters.

*You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes appearing elsewhere in this quarterly report. The following discussion contains forward-looking statements that involve risks uncertainties and assumptions. Our actual results and the timing of certain events could differ materially from those anticipated in these forward-looking statements as a result of many factors. We discuss factors that we believe could cause or contribute to these differences below and elsewhere in this quarterly report, including those set forth under “Forward-looking Statements” and “Risk Factors”, under the heading “Risk Factors” in the Company’s Annual Report, as revised and supplemented by our Quarterly Reports on Form 10-Q filed since the filing of our most recent Annual Report, and those risks described from time to time in other reports which we file with the SEC.*

### OVERVIEW

We are a specialty pharmaceutical company developing and commercializing next-generation abuse-deterrent products that incorporate our patented DETERx platform technology for the treatment of chronic pain and other diseases. Our first product, Xtampza, is an abuse-deterrent, extended-release, oral formulation of oxycodone, a widely prescribed opioid medication. In April 2016, the U.S. Food and Drug Administration, or FDA, approved our new drug application, or NDA, filing for Xtampza for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Certain human abuse potential studies are included in the approved label, as well as data supporting the administration of the product as a sprinkle or administered through feeding tubes. In June 2016, we announced the commercial launch of Xtampza, and in October 2016, we announced the submission of a New Drug Submission to Health Canada seeking marketing approval of Xtampza for the same indication for which we obtained approval from the FDA.

Xtampza has the same active ingredient as OxyContin OP, which is the largest selling abuse-deterrent, extended-release opioid in the United States by dollars, with $2.3 billion in U.S. sales in 2015. We conducted a comprehensive preclinical and clinical program for Xtampza consistent with FDA guidance on abuse-deterrence. These studies and clinical trials demonstrated that chewing, crushing and/or dissolving Xtampza, and then taking it orally or smoking, snorting, or injecting it did not meaningfully change its drug release profile or safety characteristics. By contrast, clinical trials performed by us and others — including head-to-head clinical trials comparing Xtampza with OxyContin OP — have shown that drug abusers can achieve rapid release and absorption of the active ingredient by manipulating OxyContin OP using common household tools and methods commonly available on the Internet. In October 2016, we announced the submission of a Supplemental New Drug Application to the FDA for Xtampza to include comparative oral pharmacokinetic data from a recently completed clinical study evaluating the effect of physical manipulation by crushing Xtampza compared with OxyContin OP and a control (oxycodone hydrochloride immediate-release).

In addition, our preclinical studies and clinical trials have shown that the contents of the Xtampza capsule can be removed from the capsule and sprinkled on food or into a cup, and then directly into the mouth, or administered through feeding tubes, without compromising their drug release profile, safety or abuse-deterrent characteristics. By contrast, OxyContin OP, which is formulated in hard tablets, has a black box warning label stating that crushing, dissolving, or chewing can cause rapid release and absorption of a potentially fatal dose of the active ingredient. We believe that Xtampza can address the pain management needs of the approximately 11 million patients in the United States who suffer from chronic pain and have difficulty swallowing.

In May 2016, we entered into a License and Development Agreement with BioDelivery Science International, Inc. which grants us an exclusive license to make, use, sell, offer for sale, import, develop and commercialize Onsolis in the United States. We plan to commercialize Onsolis upon receipt of FDA approval of a Prior Approval Supplement for the manufacturing transfer. Subject to such approval, we expect to launch Onsolis during the second half of 2017.

Since 2010, when we divested our former subsidiary, Onset Therapeutics, LLC, to PreCision Dermatology, Inc., we have devoted substantially all of our resources to the development of our patented DETERx platform technology, the preclinical and clinical advancement of our product candidates, pre-commercialization activities and the creation and protection of related intellectual property. Since 2011, we have not generated any significant revenue from product sales and we continue to incur significant research, development and other expenses related to our ongoing operations. Prior to our initial public offering of common stock, or IPO, in May 2015, we funded our operations primarily through the private placement of preferred stock, convertible notes and commercial bank debt. Since our IPO, we have funded our operations primarily through the proceeds of public offerings and sale of our equity securities.

### Outlook

We expect to continue to incur significant commercialization expenses related to marketing, manufacturing, distribution, selling and reimbursement activities. Initially, we plan to detail Xtampza to approximately 11,500 physicians who write more than 55% of the branded extended-release oral opioid prescriptions in the United States with a sales team of approximately 120 sales representatives. In addition, we are deploying a separate, focused sales team to detail Xtampza to nursing homes, hospices and other institutions treating large populations of the elderly and other patients who need chronic pain relief and have difficulty swallowing.

We have never been profitable and have incurred net losses in each year since inception. We incurred net losses of $66.6 million and $17.7 million for the nine months ended September 30, 2016 and 2015, respectively. As of September 30, 2016, we had an accumulated deficit of $195.6 million. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from selling, general and administrative costs associated with our operations. We expect to continue to incur net losses in the foreseeable future as we begin to commercialize Xtampza. Our net losses may fluctuate significantly from quarter to quarter and year to year. We expect our expenses may increase in connection with our ongoing activities as we:

- expand our sales and marketing efforts for Xtampza, including hiring additional personnel to expand our commercial organization;
- expand our regulatory and compliance functions;

conduct clinical trials of our product candidates;

continue scale-up and improvement of our manufacturing processes;

continue our research and development efforts;

manufacture preclinical study and clinical trial materials;

maintain, expand and protect our intellectual property portfolio;

seek regulatory approvals for our product candidates that successfully complete clinical trials;

hire additional clinical, quality control and technical personnel to conduct our clinical trials;

hire additional scientific personnel to support our product development efforts;

implement operational, financial and management systems; and

hire additional general and administrative personnel to operate as a commercial stage public company.

We believe that our cash and cash equivalents at September 30, 2016, together with expected cash inflows from the commercialization of Xtampza, as well as the proceeds of our follow-on offering completed in October 2016, will enable us to fund our operating expenses, debt service and capital expenditure requirements into 2019. Accordingly, we will seek in the future to fund our operations through additional public or private equity or debt financings or other sources. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and ability to develop and generate revenues from our products and product candidates.

### CRITICAL ACCOUNTING POLICIES AND SIGNIFICANT JUDGMENTS AND ESTIMATES

We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as “critical” because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates—which also would have been reasonable—could have been used, which would have resulted in different financial results.

The critical accounting policies we identified our Annual Report related to accrued expenses, impairment of long-lived assets, convertible redeemable preferred stock, stock-based compensation and income taxes. We have identified critical accounting policies related to inventory and revenue recognition in the interim periods ended September 30, 2016. Estimates include revenue recognition, including the estimates of discounts and allowances related to commercial sales of Xtampza, estimates utilized in the valuation of inventory, estimates of useful lives with respect to intangible assets, accounting for stock-based compensation, contingencies, intangible assets, tax valuation reserves and accrued expenses. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Our actual results may differ from these estimates under different assumptions or conditions. It is important that the discussion of our operating results that follows be read in conjunction with the critical accounting policies disclosed in the Annual Report.

### Inventory

Upon approval of Xtampza by the FDA in April 2016, we began capitalizing inventory costs for Xtampza in preparation for the product launch. Prior to April 2016, we expensed costs associated with Xtampza, including raw materials, work in process and finished goods, as research and development expense. We have not capitalized inventory costs related to our other drug development programs.

We have capitalized $1.6 million of inventory as of September 30, 2016. We expect sales of the capitalized units to occur during the next twelve months. We expect costs of product revenues to increase due to the expected increases in net product sales of Xtampza and the fact that we had expensed all manufacturing costs as research and development expense in periods prior to FDA approval of Xtampza. The impact on cost of product revenues as a result of inventory not capitalized prior to FDA approval is immaterial

### Revenue Recognition

Our accounting policy for revenue recognition will have a substantial impact on reported results and relies on certain estimates. Revenue for product sales is recognized when there is persuasive evidence of an arrangement, title and risk of loss have passed to the customer, when estimated provisions for chargebacks, rebates, sales incentives and allowances, distribution service fees, and returns are reasonably determinable, and when collectability is reasonably assured. Product sales are recorded net of estimated chargebacks, rebates, sales incentives and allowance, distribution service fees, as well as estimated product returns.

We sell Xtampza in the United States principally to customers, which in turn sell the product to healthcare providers for the treatment of patients. We provide the right of return to our customers for unopened product for a limited time before and after its expiration date. Given our limited sales history for Xtampza and the inherent uncertainties in estimating product returns, we have determined that the shipments of Xtampza made to our customers thus far do not meet the criteria for revenue recognition at the time of shipment. Accordingly, we recognize revenue when the product is sold-through by our customers, provided all other revenue recognition criteria are met. We invoice customers upon shipment of Xtampza to them and record accounts receivable, with a corresponding liability for deferred revenue equal to the gross invoice price, less any realized adjustments to the gross invoice price. We then recognize revenue when Xtampza is sold-through, or when product is prescribed directly to the patient. Healthcare providers to whom distributors sell Xtampza hold limited inventory that is designated for patients, thereby limiting the risk of return.

### RESULTS OF OPERATIONS

(in thousands)

|  | Three months ended September 30, 2016 | 2015 | Nine months ended September 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Product revenues, net | $408 | $— | $408 | $— |
| Cost of product revenues | 29 | — | 29 | — |
| Research and development | 3,254 | 3,358 | 11,617 | 6,444 |
| Selling, general and administrative | 23,567 | 5,907 | 55,266 | 11,027 |
| Other expense, net | 2 | 97 | 113 | 259 |
| Net loss | $(26,444) | $(9,362) | $(66,617) | $(17,730) |

20

### Comparison of the nine months ended September 30, 2016 and September 30, 2015

Product revenues, net were zero for the nine months ended September 30, 2015, or the 2015 Period, compared to $408,000 for the nine months ended September 30, 2016, or the 2016 Period. The $408,000 increase was due to the launch of Xtampza in June 2016.

Cost of product revenues were zero for the 2015 Period, compared to $29,000 the 2016 Period. The $29,000 increase was due to the launch of Xtampza in June 2016.

Research and development expenses were $6.4 million for the 2015 Period, compared to $11.6 million for the 2016 Period. The $5.2 million increase was primarily related to:

an increase in clinical trial costs of $4.0 million due to the commencement of clinical trials with Xtampza and our second product candidate;

- an increase in salaries, wages and benefits of $1.2 million primarily due to increased headcount and stock-based compensation expense;

an increase in manufacturing transfer costs of $499,000 related to Onsolis partially offset by;

- a decrease in consulting costs of $1.1 million primarily due to the completion of FDA advisory committee preparation in 2015.

Selling, general and administrative expenses were $11.0 million for the 2015 Period compared to $55.3 million for the 2016 Period. The $44.3 million increase was primarily related to:

- an increase in salaries, wages and benefits of $20.3 million primarily due to an increase from 12 to 201 employees and an increase in stock-based compensation expense;
- an increase in sales and marketing costs of $14.4 million primarily due to preparation for and support of the commercial launch of Xtampza;
- an increase in Post Marketing Requirement (“PMR”) costs required with FDA approval of Xtampza of $4.8 million; and
- an increase in commercial costs of $3.5 million primarily due to consultant costs related to analytics and strategies for the commercialization of Xtampza.

### Comparison of the three months ended September 30, 2016 and September 30, 2015

Product revenues, net were zero for the three months ended September 30, 2015, or the 2015 Quarter, compared to $408,000 for the three months ended September 30, 2016, or the 2016 Quarter. The $408,000 increase was due to the launch of Xtampza in June 2016.

Cost of product revenues were zero for the 2015 Quarter, compared to $29,000 for the 2016 Quarter. The $29,000 increase was due to the launch of Xtampza in June 2016.

Research and development expenses were $3.4 million for the 2015 Quarter, compared to $3.3 million for the 2016 Quarter. The $104,000 decrease was primarily related to:

- an increase in clinical trial costs of $533,000 due to the commencement of clinical trials with Xtampza and our second product candidate;
- an increase in manufacturing transfer costs of $499,000 related to Onsolis;
- an increase in salaries, wages and benefits of $369,000 primarily due to increased headcount and stock-based compensation expense offset by;
- a decrease in consulting costs of $956,000 primarily due to the completion of FDA advisory committee preparation in 2015; and
- a decrease in manufacturing costs of $657,000 mainly due to a decrease in the cost of validation batches of Xtampza.

Selling, general and administrative expenses were $5.9 million for the 2015 Quarter compared to $23.6 million for the 2016 Quarter. The $17.7 million increase was primarily related to:

- an increase in salaries and wages of $8.8 million primarily due to an increase from 12 to 201 employees and an increase in bonuses and stock-based compensation expense;
- an increase in PMR costs required with FDA approval of Xtampza of $4.8 million;
- an increase in sales and marketing costs of $2.3 million primarily due to support for the commercial launch of Xtampza; and
- an increase in commercial costs of $1.2 million primarily due to consultant costs related to analytics and strategies for the commercialization of Xtampza.

### LIQUIDITY AND CAPITAL RESOURCES

### Sources of Liquidity

We have incurred net losses and negative cash flows from operations since inception. Since inception, we have funded our operations primarily through the private placement of our preferred stock, our IPO, convertible notes and commercial bank debt. As of September 30, 2016, we had $91.0 million in cash and cash equivalents.

In January 2016, we issued and sold in a public offering an aggregate of 2,750,000 shares of our common stock at $20.00 per share. We received proceeds from this public offering of approximately $51.2 million, after deducting underwriting discounts and commissions and expenses payable by us.

Although it is difficult to predict future liquidity requirements, we believe that our existing cash, together with the net proceeds of approximately $74.8 million from our October 2016 offering, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, and expected gross profit contributions from Xtampza, will provide us with adequate cash resources to fund our operations into 2019. We have based this estimate on assumptions (including assumptions regarding the outcomes of our negotiations with payors and pharmacy benefit managers, including UnitedHealth and Cigna) that may prove to be incorrect and we could use our available capital resources sooner than we currently expect. We may never become profitable, or if we do, we may not be able to sustain profitability.

### Cash Flows

*Operating activities.* Cash used in operating activities was $51.8 million in the 2016 Period and $12.6 million in the 2015 Period. The increase in cash used in operating activities was due primarily to the change in net loss partially offset by changes in the working capital accounts. We expect cash used in operating activities to increase for the foreseeable future as we continue to commercialize Xtampza and fund research, development and clinical activities for additional product candidates.

*Investing activities.* Cash used in investing activities was $2.6 million in the 2016 Period and $175,000 in the 2015 Period. The increase in cash used in investing activities was due to the payment of a one-time upfront fee to BDSI for the Onsolis License Agreement.

*Financing activities.* Cash provided by financing activities for the 2016 Period primarily represents net proceeds of $51.6 million from the issuance of common stock partially offset by the repayment of term notes. Cash provided by financing activities for the 2015 Period primarily reflects net proceeds from the IPO and from the sale of Series D convertible preferred stock of $72.0 million and $44.8 million respectively.

### Funding Requirements

Since 2011, we have not generated any significant revenue from product sales and we continue to incur significant research, development and other expenses related to our ongoing operations. We are in the early stages of commercialization of Xtampza. We anticipate that we will continue to incur losses in the near future as we commercialize Xtampza and continue the development of, and seek regulatory approvals for, other product candidates. We are subject to all of the risks common to the commercialization and development of new pharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We will also incur additional costs associated with operating as a commercial stage public company. We anticipate that we will need substantial additional funding in connection with our continuing operations.

Until we can generate a sufficient amount of cash flow from the sale of our products, if ever, we expect to finance future cash needs through public or private equity or debt financings or other sources. Additional capital may not be available on reasonable terms, if at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could result in dilution to our existing shareholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. Any of these events could significantly harm our business, financial condition and prospects.

Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding requirements, both near- and long-term, will depend on many factors, including:

the cost of establishing sales, marketing and distribution capabilities for Xtampza and any other products for which we may receive regulatory approval;

the generation of reasonable levels of revenue from the sale of Xtampza;

the design, initiation, progress, size, timing, costs and results of preclinical studies and clinical trials for our product candidates;

the outcome, timing and cost of regulatory approvals by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than, or evaluate clinical endpoints other than those that we currently expect;

the timing and costs associated with manufacturing Xtampza and our product candidates for preclinical studies, clinical trials and, if approved, for commercial sale;

the number and characteristics of product candidates that we pursue;

the cost of patent infringement litigation, including the our litigation with Purdue Pharma, L.P., or Purdue, relating to Xtampza or our product candidates, which may be expensive to defend and delay the commercialization of our product candidates;

our need to expand our research and development activities, including our need and ability to hire additional employees;

our need to implement additional infrastructure and internal systems and hire additional employees to operate as a public company;

- our need to expand our regulatory and compliance functions; and

the effect of competing technological and market developments.

If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial condition and results of operations could be materially adversely affected.

### CONTRACTUAL OBLIGATIONS

There have been no material changes to the contractual obligations and commitments described under Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report, apart from our commitment to reimburse BioDelivery Sciences International, Inc. up to a maximum of $2.0 million for its out-of-pocket expenses incurred in conjunction with the manufacturing transfer of Onsolis.

### OFF-BALANCE SHEET ARRANGEMENTS

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

## Market risk

As filed, 606 characters.

We are exposed to market risk related to changes in interest rates. As of September 30, 2016, we had cash and cash equivalents consisting of cash and money market funds of $91.0 million. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our money market funds are short-term highly liquid investments. Due to the short-term duration and the low risk profile of our investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of our portfolio.

## Controls and procedures

As filed, 1,633 characters.

### Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2016. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2016, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

### Changes in Internal Control Over Financial Reporting

No change in our internal control over financial reporting occurred during the fiscal quarter ended September 30, 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 1,489 characters.

There are no material changes from the risk factors previously disclosed under the heading “Risk Factors” in our Annual Report, as revised and supplemented by our Quarterly Reports on Form 10-Q filed since the filing of our Annual Report and those risks described from time to time in other reports which we file with the SEC. In addition to the other information set forth in this Form10-Q, you should carefully consider the factors discussed in the Annual Report. The risks described in the Annual Report are not the only risks that we face. Additional risks not presently known to us or that we do not currently consider significant may also have an adverse effect on us. If any of the risks actually occur, our business, results of operations, cash flows or financial condition could suffer. We cannot assure you that any of the events discussed in the risk factors in the Annual Report will not occur. These risks could have a material and adverse impact on our business, results of operations, financial condition and cash flows and if so, our future prospects would likely be materially and adversely affected. If any of such events were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment. You should understand that it is not possible to predict or identify all such risks. Consequently, you should not consider the risk factors in the Annual Report to be a complete discussion of all potential risks or uncertainties.

Filed Nov 10, 2016.
Source: SEC EDGAR, the filing index for accession 0001558370-16-009927. Last ingested by Listed: Nov 10, 2026, 23:07 ET. No prices; not investment advice.
